Allegro Ophthalmics
- Company typePrivate
- Founded2011
- HeadquartersSan Juan Capistrano, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Allegro Ophthalmics firmographics
Firmographics- Name
- Allegro Ophthalmics
- Legal name
- Allegro Ophthalmics, LLC
- Website
- https://allegroeye.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Allegro Ophthalmics industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Allegro Ophthalmics is headquartered
LocationHeadquarters
- HQ city
- San Juan Capistrano
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Allegro Ophthalmics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel
Revenue model
- Licensing Royalties: Allegro Ophthalmics generates revenue through licensing agreements with pharmaceutical partners for its drug candidates. Risuteganib (Luminate®) commercial rights are retained by Allegro outside of Japan, Korea and China. Hanmi Pharmaceutical holds license for Korea and China.
- Strategic Partnerships and Option Agreements: The company entered into an agreement with Bausch Health to acquire an option to purchase all ophthalmology assets, including global rights for risuteganib. The option payment totaling $50 million would be made in two tranches.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Allegro Ophthalmics product offering
Product offeringCore offering
Allegro Ophthalmics is a clinical-stage biopharmaceutical company developing integrin-regulating therapies for ocular diseases. Its lead candidate, Risuteganib (Luminate®), is an investigational intravitreal small-peptide mitochondrial stabilizer for intermediate dry AMD, diabetic macular edema, and vitreomacular traction. A second candidate, ALG-1007, is a topical eye-drop formulation of risuteganib combined with sodium hyaluronate for dry eye disease. The company monetizes via regional pharmaceutical licenses, strategic option agreements, and grant funding while advancing candidates through FDA-regulated clinical trials.
Product overview
Allegro Ophthalmics is a biopharmaceutical company developing novel oxidative stress stabilizers and integrin-regulating therapies for treatment of ocular diseases. The company's product portfolio consists of two main investigational drug candidates: Risuteganib (Luminate®), an intravitreal injectable mitochondrial stabilizer for retinal diseases including intermediate dry AMD and diabetic macular edema, and ALG-1007, a topical eye drop formulation combining risuteganib with sodium hyaluronate for dry eye disease. Both products leverage the company's integrin-regulating mechanism of action targeting angiogenic, inflammatory, and mitochondrial metabolic pathways.
Differentiator
Problem solved
Functional benefit
Brands
- Luminate: Risuteganib (Luminate) is Allegro's lead investigational compound in retina for the treatment of dry AMD and diabetic macular edema.
- Risuteganib
- ALG-1007
Products and services
- Risuteganib (Luminate®) First-in-class integrin-regulating therapy and small-peptide mitochondrial stabilizer administered as an intravitreal injectable. Investigational candidate for intermediate dry age-related macular degeneration (dry AMD), diabetic macular edema (DME), diabetic retinopathy, and vitreomacular traction. Acts simultaneously on angiogenic, inflammatory, and mitochondrial metabolic pathways. Demonstrated 48% of patients gaining ≥8 letters of vision at week 28 vs 7% in sham (p=0.013) and 12-week durability in clinical trials.
- ALG-1007 Topical Ophthalmic Solution Topical integrin-regulating drug candidate for the treatment of dry eye disease. Fixed combination of 0.6% risuteganib and 0.125% sodium hyaluronate in a vehicle solution, administered as eye drops twice daily. Met all primary and secondary endpoints in ex-U.S. Phase 2 vehicle-controlled trial, with statistically significant improvement in dry eye signs and symptoms as early as 2 weeks. FDA accepted IND application clearing path to U.S. Phase 2b study.
Quantifiable outcome
- 48% of patients in risuteganib arm gained ≥8 letters at week 28 vs 7% in sham group (p=0.013)
- +2 more outcomes
Companies that use Allegro Ophthalmics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Allegro Ophthalmics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Allegro Ophthalmics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major.
- AffaMed TherapeuticsmajorAffaMed Therapeutics licensed risuteganib (Luminate®) for Greater China and received Clinical Trial Application (CTA) approval from China's National Medical Products Administration to investigate risuteganib for treatment of intermediate dry AMD. Under the CTA approval, Risuteganib is expected to become the first product in China to enter Phase 3 development for treatment of dry AMD. AffaMed also entered into a licensing agreement with Hanmi Pharmaceutical to develop and commercialize risuteganib in Greater China.
- Bausch Health Companies Inc.majorBausch Health (through its affiliate) entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro, including global rights for risuteganib. Option payment totaling $50 million in two tranches ($10M upon signing, $40M expected in 2021). If Bausch Health exercises the option, additional payments will be payable.
- Hanmi Pharmaceutical Co., Ltd.majorLicensing agreement for Luminate® (ALG-1001) for treatment of vitreoretinal diseases including DME, wet AMD, and VMT in The Republic of Korea and People's Republic of China. Hanmi Pharmaceutical made a $20 million strategic investment in Allegro as part of the agreement.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Allegro Ophthalmics competitors and assessment
Company assessmentEmerging players
- Annexon Biosciences: Clinical-stage biotech with ANX007 for geographic atrophy in dry AMD. Comparable as a small-cap emerging player in the dry AMD competitive set targeting complement or related neuroprotective pathways.
- Kodiak Sciences: Clinical-stage retinal biopharma developing KSI-301 (tarcocimab) for wet AMD, DME, and retinal vein occlusion. Competes for retina specialist mindshare and clinical development resources in the same indications as Allegro's DME program.
- Clearside Biomedical: Ophthalmic biotech developing suprachoroidal drug delivery platform (Xipere) for macular edema. Comparable as a small-cap clinical-stage ophthalmic biopharma focused on retinal disease drug delivery, with similar pipeline and partnership dynamics.
Direct peers
- Apellis Pharmaceuticals: Commercial-stage biopharma with pegcetacoplan (Syfovre) approved for geographic atrophy in dry AMD. Most direct competitor to Allegro in the retinal disease space targeting dry AMD indications with high unmet need.
- Aldeyra Therapeutics: Clinical-stage biotech developing reproxalap for dry eye disease and ADX-2191 for retinal conditions. Comparable late-stage clinical ophthalmic biotech with multiple ocular indications, mirroring Allegro's retina + dry eye pipeline structure.
- Iveric Bio (Astellas): Acquired by Astellas in 2023; developed Izervay (avacincaptad pegol) for geographic atrophy in dry AMD. Direct peer competing in the same dry AMD commercial opportunity as risuteganib.
- Alimera Sciences: Commercial-stage ophthalmic specialty pharma with Iluvien (fluocinolone acetonide intravitreal implant) for diabetic macular edema. Direct specialty ophthalmology pharma peer with retina-focused commercial franchise.
- Outlook Therapeutics: Clinical-to-commercial ophthalmic biopharma developing ONS-5010/LYTENAVA (bevacizumab) for wet AMD and other retinal indications, overlapping Allegro's DME/retina development footprint.
Broad incumbents
- Regeneron Pharmaceuticals: Major biopharma with EYLEA (aflibercept), the leading anti-VEGF therapy for wet AMD and DME — the standard-of-care competitor that risuteganib must demonstrate differentiation against in DME and wet AMD.
- Bausch + Lomb: Major global ophthalmic pharma and vision-care company (part of Bausch Health). Acquired ISTA Pharmaceuticals (Allegro CEO's prior company) and holds the option to acquire Allegro's assets — directly relevant as both potential acquirer and broad ophthalmology incumbent.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Allegro Ophthalmics social profiles
Digital presenceAllegro Ophthalmics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allegro Ophthalmics leadership team
Management profileNumber of profiles
Profiles12 records
Allegro Ophthalmics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allegro Ophthalmics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allegro Ophthalmics
What does Allegro Ophthalmics do?
Allegro Ophthalmics is a clinical-stage biopharmaceutical company developing integrin-regulating therapies for ocular diseases. Its lead candidate, Risuteganib (Luminate®), is an investigational intravitreal small-peptide mitochondrial stabilizer for intermediate dry AMD, diabetic macular edema, and vitreomacular traction. A second candidate, ALG-1007, is a topical eye-drop formulation of risuteganib combined with sodium hyaluronate for dry eye disease. The company monetizes via regional pharmaceutical licenses, strategic option agreements, and grant funding while advancing candidates through FDA-regulated clinical trials.
Is Allegro Ophthalmics a public or private company?
Allegro Ophthalmics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Allegro Ophthalmics founded?
Allegro Ophthalmics was founded in 2011. It employs 11 to 50 people.
Where is Allegro Ophthalmics based?
Allegro Ophthalmics is headquartered in San Juan Capistrano, United States, in the North America region.
How does Allegro Ophthalmics make money?
Two revenue lines are on record. Licensing Royalties are the primary driver. The others are strategic Partnerships and Option Agreements.
Who are Allegro Ophthalmics's main competitors?
Emerging players on record are Annexon Biosciences, Kodiak Sciences and Clearside Biomedical. Direct peers are Apellis Pharmaceuticals, Aldeyra Therapeutics, Iveric Bio (Astellas), Alimera Sciences and Outlook Therapeutics. Broad incumbents are Regeneron Pharmaceuticals and Bausch + Lomb.
Does Allegro Ophthalmics have an API?
No public API is recorded for Allegro Ophthalmics.
What industry is Allegro Ophthalmics in?
Allegro Ophthalmics's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.